Pharmassist
Pharmassist is recorded as a service provider in 19 clinical trials. Explore its recorded services, study phases and therapeutic areas, with trial-level operational learnings where available.
Clinical trial experience
Showing 19 of 19 trials · Latest update first
A Phase 3, Multicenter, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Contezolid Acefosamil and Contezolid Compared to Linezolid Administered Intravenously and Orally to Adults with Moderate or Severe Diabetic Foot Infections
Sponsor Micurx Pharmaceuticals Inc.
- Start (EU)
- Latest update
- Estimated end
A Phase 2 study of intratumoral administration of L19IL2/L19TNF in locally advanced Basal Cell Carcinoma patients progressed on or intolerant to systemic treatment.
Sponsor Philogen S.p.A.
- Start (EU)
- Latest update
- Estimated end
A Phase 2 controlled randomized study of the efficacy of L19IL2 or L19TNF or L19IL2/L19TNF intralesional injections for the treatment of locally advanced basal cell carcinoma patients.
Sponsor Philogen S.p.A.
- Start (EU)
- Latest update
- Estimated end
A phase III multicenter, double-blind, randomized, placebo-controlled, parallel-group trial of the efficacy of citicoline eye drops 2% on visual field preservation in patients with open angle glaucoma
Sponsor Omikron Italia S.r.l.
- Start (EU)
- Latest update
- Estimated end
Multicenter, randomized, double-blind, parallel-group clinical study comparing RD03/2016 (levoFloxacin and ketorolac trometAmol) eye drops vs Leviosa® (levofloxacin and dexamethaSone 21-phosphaTe) eye drops for 7 days for the prevention and treatment of inflammation and prevention of infection associated with cataract surgery in adults. (FAST 7)
Sponsor Ntc S.r.l.
- Start (EU)
- Latest update
- Estimated end
- Not reported
A follow-up extension study of patients who completed the U-LaserPrint-1 clinical trial to evaluate the long-term safety and efficacy of treatment with InvivoLPrint-U.
Sponsor Phosprint S.A.
- Start (EU)
- Not reported
- Latest update
- Estimated end
- Not reported
A Phase 2 study of intratumoral administration of L19IL2/L19TNF in locally advanced Cutaneous Squamous Cell Carcinoma patients progressing on or intolerant to systemic treatment.
Sponsor Philogen S.p.A.
- Start (EU)
- Latest update
- Estimated end
A Double-Blind, Placebo-Controlled, Crossover Pilot Study of the Efficacy and Safety of Fluasterone Buccal Tablet in the Control of Hyperglycemia in Adults with Endogenous Cushing’s Syndrome
Sponsor Sterotherapeutics LLC
- Start (EU)
- Latest update
- Estimated end
- Not reported
Randomized, double-blind, phase 2 clinical trial controlled with conventional Bacillus Calmette-Guérin (BCG) vaccine to evaluate the safety and immunogenicity of a recombinant BCG vaccine that expresses the respiratory syncytial virus (RSV) nucleoprotein (N) (rBCG-N-RSV) in adults over 60 years of age.
Sponsor Biothervax SpA
- Start (EU)
- Latest update
- Estimated end
- Not reported
A proof of concept study to evaluate treatments´efficacy by monitoring Minimal Residual Disease using ctDNA in HR-positive/HER2-negative early breast cancer population. -The MIRADOR study-
Sponsor Medica Scientia Innovation Research S.L.
- Start (EU)
- Latest update
- Estimated end
Anticoagulation for Stroke Prevention In patients with Recent Episodes of Atrial Fibrillation occurring transiently with stress - The ASPIRE-AF trial
Sponsor Hamilton Health Sciences Corporation
- Start (EU)
- Latest update
- Estimated end
A phase III, double blind, randomised, two arms, parallel study to compare the efficacy and safety of a 12-week administration of two fixed-dose combinations (Rosuvastatin 20 mg and Fenofibrate 160 mg versus Pravastatin 40 mg and Fenofibrate 160 mg (Pravafenix®)) in patients with mixed dyslipidaemia.
Sponsor Laboratoires S.M.B.
- Start (EU)
- Latest update
- Estimated end
- Not reported
A Randomized, Controlled, Multicenter Study to Evaluate the Safety and Efficacy of Paltusotine in Subjects with Non-pharmacologically Treated Acromegaly (PATHFNDR-2)
Sponsor Crinetics Pharmaceuticals Inc.
- Start (EU)
- Latest update
- Estimated end
An Exploratory, First-in-Human, study to investigate the safety and preliminary efficacy of InvivoLPrint-U-Therapy, a combination of an advanced therapy medicinal product (ATMP) of expanded autologous urothelial cells with an in vivo bioprinter for administration during orthotopic neobladder surgery
Sponsor Phosprint S.A.
- Start (EU)
- Latest update
- Estimated end
- Not reported
An open-label, phase 2 study, evaluating the efficacy of treatment with Gilteritinib in measurable residual disease eradication in patients with FLT3-ITD mutated acute myeloid leukemia
Sponsor Hellenic Society Of Hematology
- Start (EU)
- Latest update
- Estimated end
- Not reported
A RandomIzed, Double-Blind, Placebo-CoNtrolled, Two-Part Study to Evaluate the Pharmacodynamic EffIcacy and Clinical Benefit of AT 007 in Patients with SoRbitol Dehydrogenase (SORD) DEficiency
Sponsor Applied Therapeutics Inc.
- Start (EU)
- Latest update
- Estimated end
Phase I/II Study of inducible HLAG+ Regulatory T Cells (iG-Tregs) in patients undergoing HLA-matched sibling donor allogeneic haematopoietic cell transplantation.
Sponsor University Of Patras
- Start (EU)
- Latest update
- Estimated end
- Not reported
A perspective multicenter randomized clinical trial for the safety and efficacy of flecainide compared to amiodorone for the conversion of paroxysmal atrial fibrillation in the Emergency Department in patients with coronary disease without residual ischemia and ejection fraction >35% (FLECA-ED)
Sponsor Win Medica Pharmaceutical S.A.
- Start (EU)
- Latest update
- Estimated end
- Not reported
A Randomized, Open-Label Study of the Efficacy and Safety of Galinpepimut-S (GPS) Maintenance Monotherapy Compared to Investigator's Choice of Best Available Therapy in Subjects with Acute Myeloid Leukemia Who Have Achieved Complete Remission After Second-Line Salvage Therapy
Sponsor Sellas Life Sciences Group Inc.
- Start (EU)
- Latest update
- Estimated end
Questions about this trial experience
What services are recorded for Pharmassist?
The 2026-10-09 snapshot links Pharmassist to 19 distinct CTIS trials. Recorded services include Clinical monitoring, Regulatory services, Safety reporting & pharmacovigilance, Project management, among 12 recorded service labels. These are study-specific roles, not a complete or independently verified capability catalogue.
Which therapeutic areas and study phases are recorded for Pharmassist?
The most frequently recorded therapeutic areas are Solid Tumor Oncology, Dermatology, Endocrinology, Infectious Disease. Recorded phases include Phase 2, Phase 3, Phase 1. Use the filters to inspect the supporting studies; missing tags are not evidence of absent experience.
In which countries are trials linked to Pharmassist conducted?
The linked trials record locations in 24 countries, including Greece, Italy, Spain, France, Germany. These are trial locations, not confirmed office locations or countries where Pharmassist delivered services.
What can this page tell me about Pharmassist's trial experience?
Browse 19 distinct trials with recorded roles, sponsor names, available study dates and links to CTIS source records. No trial-level operational findings are recorded in this snapshot. Trial counts and findings do not measure the provider’s performance or establish responsibility for study outcomes.
About this data & company names
One current approved profile per CTIS trial. Services reflect recorded roles, not a complete capability catalogue or a performance ranking. Missing tags mean the information was not recorded. Country tags describe trial locations, not the provider’s service territory.
Start is the reported EU start date; latest update is the CTIS publication date; estimated end is the reported global estimate, which may be in the past. Missing dates are shown as “Not reported”. Operational learnings describe the trial as a whole and do not establish the provider’s responsibility.
Clear service synonyms are grouped; otherwise the source label is retained. Service tags show the recorded roles for each trial. This page groups 1 recorded name variant under Pharmassist. Legacy brands remain separate unless explicitly matched in the name registry.
View recorded company names
- Pharmassist Ltd.